Introducing the Pharma Fast 50
PharmaTimes presents Alantra’s annual look at the fastest-growing pharma companies
PharmaTimes -
March 2019
In this issue, we present Alantra’s annual ranking of the 50 fastest-growing, privately owned pharma companies. Of particular note, every single company on this list has delivered annualised revenue growth in double digits, an impressive feat during the current climate of economic uncertainty. But who tops the list? Who are the greatest movers and shakers? Take a look on page 20.
Elsewhere, we consider the long-awaited NHS Long Term Plan and what the future of the heath service might look like over the next decade (p16). Where does pharma fit into this new blueprint?
We also delve into the innovations helping to change the landscape for clinical research (p28), how clinical trials are entering a radically new dimension (p31), and how pharma is wrestling with the new ‘right to be forgotten’, brought in by the GDPR last year (p38).
On page 40 is an interview with Lotte Bjerre Knudsen, inventor of diabetes drug liraglutide and scientific vice president at Novo Nordisk, who gives a fascinating insight into her role and thoughts on the sector.
Finally, PharmaTimes is gearing up to launch the 2019 Sales Awards, Marketer of the Year and Communications Team of the Year competitions – we’ll keep you posted!
I hope you enjoy the issue.
March 2019 - magazine highlights
Resistance is futile
An exciting, futuristic chapter for clinical trials has opened in which participant engagementwill flourish, expansive data will navigate the maze of disease and digital technology will take pharma and patients to previously unexplored dimensions. John Pinching reports.
What does the next decade hold for the NHS?
Steve How and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore some of the key aspirations of the NHS’ Long Term Plan
Closing the gap
How seven innovations are accelerating research and bringing new data-driven insights to the clinical trial landscape, potentially reducing the time and cost of drug development
SmartPeople: Lotte Bjerre Knudsen
PharmaTimes talks to Lotte Bjerre Knudsen, inventor of diabetesdrug liraglutide and scientific vice president at Novo Nordisk
The rise of the CRO
Dr Chris Doherty discusses the rise of clinical research organisations (CROs) from his vantage point as managing director at Alderley Park
A need to know basis
Ten months since sweeping data privacy laws came into force in Europe, pharma companies are wrestling with the new ‘right to be forgotten’
SmartPeople: Richard Davies
Richard Davies, vice president and solutions expert at CluePoints, says there’s “a huge opportunity” for operational efficiency gains in clinical trials
